
-
Kura Oncology NasdaqGS:KURA Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC. The company is headquartered in San Diego, California.
Location: 12730 High Bluff Drive, San Diego, CA, 92130, United States | Website: https://kuraoncology.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-146.2M
Cash
658.2M
Avg Qtr Burn
N/A
Short % of Float
12.40%
Insider Ownership
1.09%
Institutional Own.
94.32%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ziftomenib + Induction Chemotherapy (7+3) Details Blood cancer, Acute myeloid leukemia, Cancer | Phase 3 Initiation | |
Ziftomenib + venetoclax + azacitidine Details Blood cancer, Acute myeloid leukemia, Cancer | Phase 3 Initiation | |
Tipifarnib + alpelisib Details Head and neck cancer, Head and neck squamous cell carcinoma, Cancer | Phase 1/2 Data readout | |
Ziftomenib Details Acute myeloid leukemia, Blood cancer, Cancer | Phase 1/2 Data readout | |
Ziftomenib + venetoclax/azacitidine Details Blood cancer, Acute myeloid leukemia, Cancer | Phase 1b Data readout | |
Ziftomenib + venetoclax/azacitidine (ven/aza) or cytarabine/daunorubicin (7+3) Details Blood cancer, Acute myeloid leukemia, Cancer | Phase 1b Data readout | |
Ziftomenib + gilteritinib Details Acute myeloid leukemia, Blood cancer, Cancer | Phase 1 Data readout | |
Ziftomenib + imatinib Details Gastrointestinal stromal tumors | Phase 1 Data readout | |
KO-2806 +cabozantinib Details Advanced Renal Cell Carcinoma | Phase 1 Data readout | |
KO-2806 Monotherapy Details Renal Cell Carcinoma | Phase 1 Data readout | |
KO-2806 Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Phase 1 Data readout | |
KO-2806 + cabozantinib Details Solid tumor/s, Renal cell carcinoma, Cancer | Phase 1 Data readout | |
Tipifarnib Details Cancer, T-cell lymphoma, Lymphoma | Failed Discontinued | |
Tipifarnib Details Head and neck cancer, Cancer, Head and neck squamous cell carcinoma | Failed Discontinued |